Failure of vitamin C to affect the pharmacokinetic profile of antipyrine in man.
A possible interaction of vitamin C with the metabolism of drugs which are oxidized (e.g., antipyrine and diphenylhydantion) is indicated from data in animals. The effect of megadoses of vitamin C (300 mg/day to 4800 mg/day) was therefore tested in human volunteers receiving antiprine (single oral dose) or diphenlhydantoin (chronic therapy). The half-life, volume of distribution, and plasma clearance of antipyrine were not affected by vitamin C treatment. Steady-state plasma levels of diphenylhydantoin in two epileptic patients were similar before and during vitamin C (1.2 Gm/day for 18 days) treatment. It is concluded that vitamin C, in commonly used megadoses, has no effect on the metabolism of antipyrine or diphenylhydantoin in men.
D000983:Antipyrine / Q000097:blood*; D001205:Ascorbic Acid / Q000494:pharmacology*; D004827:Epilepsy / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D010672:Phenytoin / Q000097:blood; D012907:Smoking
D010672:Phenytoin; D001205:Ascorbic Acid; D000983:Antipyrine